Colchicine and lasting leg problems after a deep vein clot
Tests colchicine in people with a deep leg vein clot.
Key facts
- Who runs it
- Ottawa Hospital Research Institute
- Where
- Canada4 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 150 people, planned
- Started
- 7 Jul 2025
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Colchicine 0.5 mg po
- Placebo 0.5 mg po
- Record updated
- 23 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a first, sudden blood clot in a deep vein of the leg, at or above the knee. It tests whether low-dose colchicine lowers the risk of long-term leg problems after the clot.
- Age
- 18 years or older
- Sex
- All
- Disease stage
- A first, acute deep vein thrombosis (DVT) of the leg that causes symptoms. It must be in the popliteal vein (behind the knee) or higher, and confirmed by a test.
- Earlier treatment
- People cannot join if they used systemic immunosuppressive drugs (such as steroids, tumor necrosis factor-alpha blockers, cyclosporine) in the last 30 days or long term.
Main reasons for not taking part
- Allergy or strong sensitivity to colchicine, or already needing colchicine for another reason
- Ongoing diarrhea, inflammatory bowel disease, irritable bowel syndrome or blood disorders
- Recent (<30 days) or active infection, known active cancer, or serious liver disease such as cirrhosis
- Liver enzymes >3 times or bilirubin >2 times the upper limit of normal, or creatinine clearance <30 mL/min
- Pregnancy, breastfeeding, planning pregnancy, or not willing to use birth control; use of interacting drugs such as erythromycin or clarithromycin
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Consenting patients 18 years of age or older with a first, acute, symptomatic proximal (popliteal vein or more proximal) objectively confirmed DVT of the lower extremity will be eligible to participate in the study
Who cannot take part
- Recent (<30 days) or chronic use of systemic (oral, intravenous) immunosuppressive drugs (including but not limited to steroids, tumor necrosis factor-alpha blockers, cyclosporine)
- The use of medication with known drug-to-drug interactions (including but not limited to erythromycin or clarithromycin)
- History of an allergic reaction or significant sensitivity to colchicine
- Active or chronic diarrhea, or documented inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis), collagenous colitis or irritable bowel syndrome or existing blood dyscrasias
- Known or suspected, recent (<30 days) or active infections (acute or chronic)
- History of cirrhosis, chronic active hepatitis, or severe liver disease
- Known active cancer
- Any of the following as measured within the past 1-3 months or at screening: alanine, or aspartate aminotransferase >3 times the upper limit of normal, total bilirubin >2 times the upper limit of normal and a creatinine clearance by Cockcroft-Gault formula <30 mL/min
- Requirement of colchicine for other indications
- Pregnancy, breast feeding or may be considering pregnancy during the study period or women of childbearing potential unwilling to use appropriate contraception during sex
- Unable or unwilling to provide consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This trial seeks to assess the feasibility of a full-scale, double-blind, placebo-controlled, randomized trial assessing whether low-dose colchicine (0.5 mg daily) reduces the risk of post-thrombotic syndrome (PTS) in patients with proximal lower extremity deep vein thrombosis (DVT).
The 2 groups in the trial
- Experimental Arm: ColchicineTreatment being tested
Colchicine 0.5 mg po once daily for 180 days. After the Day - 180 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
Treatment: Colchicine 0.5 mg po
- Control Arm : PlaceboPlacebo, for comparison
Placebo 0.5 mg po once daily for 180 days. After the Day - 180 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
Treatment: Placebo 0.5 mg po
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis: A Randomized Controlled Pilot Trial
- Plain-language title
- Colchicine and lasting leg problems after a deep vein clotGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 23 July 2026